

CITATION REPORT

List of articles citing

Prevalence of cardiovascular risk factors in patients with psoriasis

DOI: 10.1016/j.jaad.2006.08.040

Journal of the American Academy of Dermatology,
2006, 55, 829-35.

Source: <https://exaly.com/paper-pdf/39914622/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
828	.		
827	Psoriatic disease--from skin to bone. 2007 , 3, 698-706		64
826	Update on the epidemiology and systemic treatment of psoriasis. 2007 , 3, 171-85		18
825	The risk of mortality in patients with psoriasis: results from a population-based study. 2007 , 143, 1493-9		347
824	Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. 2007 , 167, 1670-5		303
823	Psoriasis: advances in pathophysiology and management. 2007 , 83, 690-7		26
822	Long-term treatment for severe psoriasis: we're halfway there, with a long way to go. 2007 , 143, 1191-3		8
821	Incidence and risk factors for psoriasis in the general population. 2007 , 143, 1559-65		226
820	Cardiovascular risk factors and myocardial infarction in patients with psoriasis. 2007 , 2, 19-23		
819	Prevalence of cardiovascular risk factors in patients with psoriasis. 2007 , 2007, 90-92		
818	La psoriasis, ¿una enfermedad sistémica?. 2007 , 98, 396-402		24
817	Pathogenesis and clinical features of psoriasis. 2007 , 370, 263-271		1221
816	Heart disease in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2007 , 57, 347-54	4.5	127
815	Psoriasis, a Systemic Disease?. 2007 , 98, 396-402		3
814	Update on infliximab: an intravenous biologic therapy for psoriasis. 2007 , 2, 707-713		2
813	Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. 2007 , 143, 1025-30		81
812	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. 2007 , 157, 68-73		445

811	Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. 2007 , 157, 649-55		236
810	Is hypertension an immunologic disease?. 2008 , 10, 464-9		64
809	The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. 2008 , 300, 545-50		11
808	Association between serious ischemic cardiac outcomes and medications used to treat diabetes. 2008 , 17, 753-9		84
807	Reply. 2008 , 59, 455-456		
806	Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-alpha inhibition. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 300-10	4.3	28
805	Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 341-4	4.6	137
804	Haptoglobin from psoriatic patients exhibits decreased activity in binding haemoglobin and inhibiting lecithin-cholesterol acyltransferase activity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 417-25	4.6	5
803	Psoriasis and diabetes: a population-based cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 585-9	4.6	121
802	The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. 2008 , 158, 1141-3		17
801	Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. 2008 , 158, 1299-307		52
800	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. 2008 , 159, 322-30		155
799	Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. 2008 , 159, 342-50		175
798	Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. 2008 , 159, 895-902		202
797	Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. 2008 , 159, 704-10		65
796	Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. 2008 , 159, 820-6		122
795	Psoriasis and chronic obstructive pulmonary disease: a case-control study. 2008 , 159, 956-60		64
794	Long-term prognosis in patients with psoriasis. 2008 , 159 Suppl 2, 2-9		73

793	Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. 2008 , 159 Suppl 2, 10-7		148
792	Psoriasis and the risk of incident diabetes mellitus: a population-based study. 2008 , 159, 1331-7		84
791	The editor's roundtable: psoriasis, inflammation, and coronary artery disease. 2008 , 101, 1119-26		22
790	AJC editor's consensus: psoriasis and coronary artery disease. 2008 , 102, 1631-43		124
789	Efalizumab in the treatment of psoriasis: when comorbidity is an issue. 2008 , 21 Suppl 2, S25-9		4
788	Update on the natural history and systemic treatment of psoriasis. 2008 , 24, 171-96		26
787	[Psoriasis, metabolic syndrome and its components]. 2008 , 135 Suppl 4, S235-42		8
786	Psoriasis: the heart of the matter. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 477-8	4.5	1
785	Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 421-9	4.5	50
784	Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 625-31	4.5	107
783	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 1031-42	4.5	329
782	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 826-50	4.5	958
781	The impact of psoriasis on health care costs and patient work loss. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 772-80	4.5	115
780	Potential misclassification of patients with psoriasis in electronic databases. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 981-5	4.5	48
779	Psoriasis and vascular disease: an unsolved mystery. 2008 , 121, 360-5		21
778	Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. 2008 , 26, 554-61		5
777	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). 2008 , 371, 1665-74		1296
776	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). 2008 , 371, 1675-84		1150

775	[Addictions and psoriasis: an example of the dermatologist's implication in preventive medicine ?]. 2008 , 135 Suppl 4, S259-62	5
774	Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. 2008 , 47, 718-23	193
773	Psoriasis and dilated cardiomyopathy: coincidence or associated diseases?. 2008 , 111, 202-6	19
772	Psoriasis comorbidities. 2008 , 19, 5-21	183
771	Cytokine milieu in psoriasis and cardiovascular disease may explain the epidemiological findings relating these 2 diseases. 2008 , 144, 1518-9	16
770	Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. 2008 , 144, 1571-5	112
769	Medical history, drug exposure and the risk of psoriasis. Evidence from an Italian case-control study. 2008 , 216, 125-30; discussion 130-2	37
768	Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. 2008 , 217, 27-37	135
767	Treatment of Psoriasis. 2008 ,	1
766	Moderate-to-Severe Psoriasis. 2008 ,	
765	Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. 2008 , 217, 365-73	167
764	Psoriasis: a possible risk factor for development of coronary artery calcification. 2008 , 2008, 110-111	
763	Psoriasis and metabolic disease: epidemiology and pathophysiology. 2008 , 20, 416-22	182
762	Cardiometabolic risk in psoriasis: differential effects of biologic agents. 2008 , 4, 1229-35	15
761	Moderate and severe plaque psoriasis: cost-of-illness study in Italy. 2008 , 4, 559-68	54
760	Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. 2009 , 19, 252-6	25
759	[Skin manifestations, treatment and rehabilitation in overweight and obesity]. 2009 , 150, 1731-8	4
758	Biologics in the management of psoriasis. 2009 , 2, 111-28	8

757	Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. 2009 , 20, 42-7	30
756	A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. 2009 , 13, 294-302	19
755	Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. 2009 , 145, 700-3	266
754	Chronic plaque psoriasis is associated with increased arterial stiffness. 2009 , 218, 110-3	93
753	Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. 2009 , 35, 313-24	74
752	Inflammatory arthritis: an overview for primary care physicians. 2009 , 121, 148-62	4
751	Psoriasis [eine Volkskrankheit im Umbruch]. 2009 , 35, 7-14	
750	Impact of comorbidities on the management of psoriasis. 2009 , 38, 21-36	12
749	The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. 2009 , 13, 283-93	20
748	Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. 2009 , 89, 492-7	99
747	Epidemiological study of psoriasis in the national health insurance database in Taiwan. 2009 , 89, 262-6	85
746	Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. 2009 , 89, 476-83	21
745	Psoriasis comorbidities. 2009 , 13 Suppl 2, S77-87	26
744	Psoriatic arthritis: pharmacoeconomic considerations. 2009 , 11, 263-9	8
743	[Therapeutic strategies for psoriasis and psoriatic arthritis]. 2009 , 60, 91-9	0
742	Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. 2009 , 48, 379-87	23
741	Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. 2009 , 48, 1147-56	30
740	Psoriasis arthropathica associated with severe obesity showing high serum leptin level. 2009 , 36, 364-6	3

739	Psoriasis: an opportunity to identify cardiovascular risk. 2009 , 160, 1-7		46
738	Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. 2009 , 160, 1048-56		145
737	Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. 2009 , 161 Suppl 2, 1-30		5
736	Lichen planus and dyslipidaemia: a case-control study. 2009 , 161, 626-9		71
735	More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. 2009 , 161, 1-7		99
734	Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. 2009 , 34, 140-4		62
733	Psoriasis and osteoporosis: a sex-specific association?. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 1643-9	4-3	39
732	The risk of stroke in patients with psoriasis. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2411-8	4-3	304
731	Vascular disease in psoriasis. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2327	4-3	5
730	Psoriasis--a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. 2009 , 7, 946-52		10
729	Psoriasis --eine systemische Entzündung: Klinik, Pathogenese und Therapieziele. 2009 , 7, 946-952		21
728	Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. 2009 , 22, 61-73		72
727	Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 1-6	4.6	135
726	Serum and tissue expression of transforming growth factor beta 1 in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 406-9	4.6	24
725	Myocardial perfusion is preserved in patients with psoriasis without clinically evident cardiovascular disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 798-802	4.6	4
724	Psoriasis and systemic inflammation: underdiagnosed enthesopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23 Suppl 1, 3-8	4.6	46
723	Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 885-92	4.6	82
722	Treatment strategies for early psoriatic arthritis. 2009 , 10, 271-82		14

721	Progress in understanding the immunopathogenesis of psoriasis. 2009 , 100 Suppl 2, 2-13		68
720	Cardiometabolic comorbidities and the approach to patients with psoriasis. 2009 , 100 Suppl 2, 14-21		22
719	The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 218-24	4.5	362
718	Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 225-30	4.5	61
717	Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 604-8	4.5	53
716	Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 1032-6	4.5	12
715	The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 405-10	4.5	81
714	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. 2009 , 51, 758-64		179
713	Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. 2009 , 51, 778-86		170
712	Comorbidities in patients with psoriasis. 2009 , 122, 1150.e1-9		125
711	Ustekinumab: a new option in psoriasis therapy. 2009 , 69, 1141-52		29
710	Comorbidities in dermatology. 2009 , 27, 137-47, vi		23
709	Clinical spectrum and severity of psoriasis. 2009 , 38, 1-20		40
708	Cardiovascular morbidity in psoriatic arthritis. 2009 , 68, 1131-5		208
707	Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. 2009 , 174, 1443-58		69
706	New insights into the pathogenesis and genetics of psoriatic arthritis. 2009 , 5, 83-91		90
705	Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. 2009 , 2009, 109-110		
704	Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. 2009 , 2009, 111-112		

703	Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. 2009 , 145, 379-82			171
702	More than skin deep: dyslipidemia in skin diseases. 2009 , 4, 533-536			
701	Advantages in early recognition and treatment of psoriatic arthritis. 2010 , 5, 461-473			1
700	Psoriasis and cardiovascular diseases. 2010 , 65, 337-40			11
699	Psoriasis y síndrome metabólico. 2010 , 25, 133-145			7
698	Psoriasis and the metabolic syndrome. 2010 , 23, 137-43			51
697	Psoriasis and cardiovascular disease. 2010 , 23, 144-51			56
696	Psoriasis and serum lipid abnormalities. 2010 , 23, 160-73			13
695	The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 548-54	4.6		103
694	Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24 Suppl 2, 2-9	4.6		44
693	Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24 Suppl 2, 23-30	4.6		98
692	Relationships between obesity and the clinical severity of psoriasis in Taiwan. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 1035-9	4.6		23
691	Psoriatic disease: concepts and implications. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 627-30	4.6		14
690	Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 1135-43	4.6		25
689	Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 1371-7	4.6		31
688	Psoriasis: is the impairment to a patient's life cumulative?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 989-1004	4.6		127
687	How do regional factors influence psoriasis patient care in Germany?. 2010 , 8, 516-24			14
686	Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. 2010 , 49, 642-6			46

685	Psoriasis and extra domain A fibronectin loops. 2010 , 163, 5-11	26
684	Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. 2010 , 163, 586-92	274
683	Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life. 2010 , 35, 717-22	29
682	Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 962-7 4:3	117
681	Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007*. 2010 , 27, 938-48	44
680	Statin Use and Psoriasis Severity. 2010 , 16a, 20-22	
679	Comorbidities in Psoriasis. 2010 , 16a, 23-30	
678	Psoriasis and obesity: literature review and recommendations for management. 2010 , 85, 355-60	27
677	The psoriasiform reaction pattern. 2010 , 71-91.e18	2
676	Effects vs Improvement of Photoaged SkinReply. 2010 , 146,	
675	Diet and weight loss as a treatment for psoriasis. 2010 , 146, 544-6	9
674	Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. 2010 , 55, 500-7	510
673	Effects vs improvement of photoaged skin. 2010 , 146, 546-9; discussion 549-50	
672	Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. 2010 , 37, 1386-94	93
671	Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. 2010 , 8, 331-4	75
670	Prevalence of metabolic syndrome in patients with psoriasis. 2010 , 76, 662-5	63
669	Impaired aortic elastic properties in normotensive patients with psoriasis. 2010 , 19, 351-8	17
668	Psoriasis and hypertension: a case-control study. 2010 , 90, 23-6	61

667	Psoriasis and cardiovascular risk: strength in numbers. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 919-22	4-3	42
666	Lipid disturbances in psoriasis: an update. 2010 , 2010,		66
665	High body mass index in adolescent girls precedes psoriasis hospitalization. 2010 , 90, 488-93		26
664	Managing Parkinson's disease during surgery. 2010 , 341, c5718		46
663	[Psoriasis as an independent risk factor for development of coronary artery disease]. 2010 , 135, 1749-54		1
662	Clinical development of oncept, a tumor necrosis factor binding protein, in psoriasis. 2010 , 26, 2287-300		9
661	The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities. 2010 , 10, 1197-208		17
660	Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. 2010 , 31, 1000-6		472
659	Incidence of psoriasis in children: a population-based study. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 979-87	4-5	158
658	Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 448-56	4-5	115
657	Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 1058-69	4-5	87
656	The use of cyclosporine in dermatology: part II. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 949-72; quiz 973-4	4-5	72
655	Nutrition and psoriasis. 2010 , 28, 615-26		42
654	Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. 2010 , 123, 350-7		79
653	Pokes, papules, plaques. 2010 , 123, 514-6		1
652	Can early treatment with biologicals modify the natural history of comorbidities?. 2010 , 23, 181-93		17
651	Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. 2010 , 69, 2114-7		146
650	Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. 2010 , 341, c5623		33

649	The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. 2010 , 14, 81-93		28
648	Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. 2010 , 10, 1105-12		5
647	[Guide for therapeutic education program in psoriasis]. 2011 , 138, 337-53		2
646	[Current topics in psoriasis]. 2011 , 138, H1-5		
645	Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. 2011 , 63, 40-6		221
644	Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). 2011 , 63, 154-63		157
643	Psoriasis and Obesity: A Review and Practical Recommendations. 2011 , 102, 505-509		
642	The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. 2011 , 7, 9-13		31
641	[Psoriasis and obesity: a review and practical recommendations]. 2011 , 102, 505-9		9
640	Common oral mucosal diseases, systemic inflammation, and cardiovascular diseases in a large cross-sectional US survey. 2011 , 161, 344-50		39
639	Attributable risk estimate of severe psoriasis on major cardiovascular events. 2011 , 124, 775.e1-6		206
638	Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 495-501	4-5	61
637	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 671-81	4-5	64
636	Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 537-545	4-5	53
635	Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 1135-44	4-5	78
634	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 137-74	4-5	343
633	A Strategic Approach to Setting the Research Agenda in Psoriasis. 2011 , 17a, 97-102		3
632	Ustekinumab: differential use in psoriasis. 2011 , 4, 93-9		4

631	Reviewing concepts in the immunopathogenesis of psoriasis. 2011 , 86, 1151-8		17
630	Increased Prevalence of Sleep Disorders and Medical Comorbidities in Psoriatic Arthritis Patients Compared with Patients with and without Psoriasis. 2011 , 17a, 209-215		0
629	C-Reactive Protein and Cardiovascular Disease in Psoriasis. 2011 , 17a, 24-32		
628	[Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data]. 2009 , 61, 298-305		9
627	Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. 2011 , 21, 761-70		27
626	Use of pharmacogenomics in psoriasis. 2011 , 1, 399-411		4
625	Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. 2011 , 21, 510-4		19
624	A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. 2011 , 164, 26-32		25
623	Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. 2011 , 164, 103-9		38
622	Validity of The Health Improvement Network (THIN) for the study of psoriasis. 2011 , 164, 602-9		80
621	Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. 2011 , 164 Suppl 1, 1-14		81
620	Psoriasis comorbidities: a worldwide problem?. 2011 , 165, 929		
619	Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. 2011 , 36, 473-8		30
618	Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. 2011 , 270, 237-44		46
617	Economic burden of comorbidities in patients with psoriasis is substantial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 157-63	4.6	83
616	Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 705-9	4.6	37
615	Pregnancy outcomes in women with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1041-7	4.6	42
614	Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1282-7	4.6	29

613	The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1328-33	4.6	38
612	Strategies for improving the quality of care in psoriasis with the use of treatment goals—a report on an implementation meeting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25 Suppl 3, 1-13	4.6	35
611	Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1007-11	4.6	122
610	Lipid peroxidation-induced VEGF expression in the skin of KKAY obese mice. 2011 , 20, 388-93		6
609	The association of psoriasis and elevated blood lipids in overweight and obese children. 2011 , 159, 577-83		81
608	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. 2011 , 164, 862-72		93
607	Association between psoriasis and incident cancer: the Iowa's Women's Health Study. 2011 , 22, 1003-10		31
606	Influence of endothelial nitric oxide synthase polymorphisms in psoriasis risk. 2011 , 303, 445-9		13
605	Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis. 2011 , 26, 481-5		37
604	Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. 2011 , 54, 2745-54		89
603	Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. 2011 , 26, 1036-49		62
602	Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. 2011 , 63, 195-202		130
601	Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. 2011 , 15, 37-47		21
600	Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. 2011 , 147, 1031-9		157
599	Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis. 2011 , 6, 135-155		3
598	Role of childhood obesity in atopic dermatitis. 2011 , 6, 635-642		8
597	Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 1159-66	4.3	65
596	Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. 2011 , 306, 864-71		202

595	Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. 2011 , 147, 419-24	195
594	Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement. 2011 , 39, 1573-88	11
593	The Traditional Chinese Medicine syndromes of psoriasis in Chinese patients: Contribution of demographic and clinical variables. 2011 ,	
592	Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis--a pilot study. 2011 , 71, 269-73	13
591	Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders. 2011 , 22, 90-101	6
590	Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. 2012 , 92, 349-52	25
589	Obesity and risk of incident psoriatic arthritis in US women. 2012 , 71, 1267-72	115
588	Plasma and tissue chemerin levels and their relation to metabolic syndrome in patients with psoriasis. 2012 , 9, 118-122	
587	Psoriasis vulgaris severity and body mass index. 2012 , 9, 86-91	
586	Biochemical markers of psoriasis as a metabolic disease. 2012 , 50, 155-70	21
585	Dyslipidemia in granuloma annulare: a case-control study. 2012 , 148, 1131-6	33
584	Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 291-8	4-3 46
583	Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. 2012 , 71, 480-3	33
582	Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. 2012 , 33, 2054-64	161
581	Psoriasis ve Obezite. 2012 , 46, 3-6	1
580	Metabolic syndrome in psoriasis. 2012 , 5, 356-362	2
579	A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. 2012 , 2012, 965385	18
578	Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study. 2012 , 224, 31-7	23

577	Skin inflammation and cardiovascular health. 2012 , 16, 291-4		
576	Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. 2012 , 22, 337-44	4.6	46
575	Biologic therapy in psoriasis: perspectives on associated risks and patient management. 2012 , 16, 153-68		23
574	38th Annual Meeting of the Society for Pediatric Dermatology July 11-14, 2011 [Monterey, CA Presented Posters (pdfs of the posters can be found at www.pedsderm.net) Atopic Dermatitis. 2012 , 29, 679-706		
573	Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1262-8	4.6	27
572	Current investigational drugs in psoriasis. 2012 , 21, 473-87		27
571	Emerging therapies for the treatment of psoriasis. 2012 , 2, 16		9
570	Psoriasis: Ustekinumab and Other Biologics in the Pipeline. 2012 , 1, 108-114		1
569	Psoriasis is associated with increased intima-media thickness--the Study of Health in Pomerania (SHIP). 2012 , 225, 486-90		34
568	Ustekinumab y seguridad cardiovascular. 2012 , 103, 31-38		
567	The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. 2012 , 2, e54		281
566	Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. 2012 , 17, 171-6		30
565	[Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities]. 2012 , 103 Suppl 1, 1-64		25
564	Psoriasis alters HDL composition and cholesterol efflux capacity. 2012 , 53, 1618-24		109
563	Metabolic syndrome in patients with psoriatic disease. 2012 , 89, 24-8		58
562	[Multiplatform application to determine presence of metabolic syndrome and cardiovascular risk in patients with psoriasis]. 2012 , 103, 111-9		2
561	Psoriasis: a skin disease associated with increased cardiovascular risk. 2012 , 103, 595-8		12
560	Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 252-8	4.5	46

559	Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 76-85	4.5	80
558	Trends in lipid profiles in patients with psoriasis: a population-based analysis. 2012 , 12, 20		14
557	Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis. 2012 , 10, 37		10
556	Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. 2012 , 167, 1374-81		40
555	Psoriasis: rationale for targeting interleukin-17. 2012 , 167, 717-24		103
554	Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. 2012 , 148, 995-1000		100
553	A review of health outcomes in patients with psoriasis. 2012 , 30, 61-72, viii		26
552	Integrated Approach to Comorbidity in Patients With Psoriasis. 2012 , 103, 1-64		5
551	Multiplatform Application to Determine Presence of Metabolic Syndrome and Cardiovascular Risk in Patients With Psoriasis. 2012 , 103, 111-119		
550	Psoriasis: a Skin Disease Associated With Increased Cardiovascular Risk. 2012 , 103, 595-598		
549	Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 357-62	4.5	47
548	Risks of developing psychiatric disorders in pediatric patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 651-7.e1-2	4.5	114
547	Consensus guidelines for the management of plaque psoriasis. 2012 , 148, 95-102		135
546	Systemic Cyclosporin in the Treatment of Psoriasis. 2012 ,		0
545	Psoriasis and cardiovascular disease: epidemiology, mechanisms, and clinical implications. <i>Psoriasis: Targets and Therapy</i> , 2012 , 1	2.4	1
544	Psoriasis and Diabetes. 2012 ,		1
543	Cardiovascular Disease in Inflammatory Disorders - Psoriasis and Psoriatic Arthritis. 2012 ,		
542	The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients. 2012 ,		

541	Juvenile Psoriasis: A Systematic Review of Comorbid Diseases. 2012 , 18a, 57-71		
540	Metabolic Features in Psoriasis. 2012 ,		
539	Inflammation cutané et santé cardiovasculaire. 2012 , 16, 293-294		
538	Impact of Accountable Care Organizations on Psoriasis Care. 2012 , 18a, 221-224		
537	Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis. <i>Psoriasis: Targets and Therapy</i> , 2012 , 55	2.4	1
536	Psoriasis: Epidemiology, Clinical and Histological Features, Triggering Factors, Assessment of Severity and Psychosocial Aspects. 2012 ,		3
535	Remisión de la psoriasis luego de bypass gástrico. 2012 , 64, 189-193		
534	Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis. 2012 , 24, 11-5		34
533	Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. 2012 , 4, 261-8		12
532	Psoriasis: epidemiology, natural history, and differential diagnosis. <i>Psoriasis: Targets and Therapy</i> , 2012 , 67	2.4	4
531	Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. 2012 , 22, 877-80		51
530	Managing cardiovascular risk in patients with chronic inflammatory diseases. 2012 , 31, 585-94		16
529	Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 59-65	4.6	31
528	Plasma and tissue osteopontin in relation to plasma selenium in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 66-70	4.6	16
527	Advanced protein glycation in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 172-9	4.6	16
526	Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 348-53	4.6	26
525	Psoriasis and hypertension: a case-control study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 785-8	4.6	21
524	The concept of psoriasis as a systemic inflammation: implications for disease management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26 Suppl 2, 3-11	4.6	188

523	Psoriasis and physical activity: a review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 1345-53	4.6	30
522	Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population. 2012 , 53, 128-30		21
521	Vessel resistance to blood flow in the nailfold in patients with psoriasis: a prospective case-control echo Doppler-based study. 2012 , 166, 54-8		23
520	Association between atopic dermatitis and obesity in adulthood. 2012 , 166, 498-504		73
519	Coronary artery disease in patients with psoriasis referred for coronary angiography. 2012 , 109, 976-80		74
518	Psoriasis and metabolic syndrome. 2012 , 39, 212-8		80
517	Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring. 2012 , 39, 1074-5		1
516	The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. 2012 , 53, 190-7		52
515	Psoriasis increased the risk of diabetes: a meta-analysis. 2012 , 304, 119-25		35
514	Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. 2013 , 52, 681-3		18
513	Behçet's disease in concurrence with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, e113-8	4.6	9
512	Body weight increment in patients treated with infliximab for plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, e186-90	4.6	36
511	Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 820-6	4.6	30
510	A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 899-906	4.6	26
509	Bioactive Dietary Factors and Plant Extracts in Dermatology. 2013 ,		1
508	Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27 Suppl 3, 12-29	4.6	199
507	Effectiveness and safety of psoralen-UVA (PUVA) topical therapy in palmoplantar psoriasis: a report on 48 patients. 2013 , 104, 418-25		6
506	Prevalence of the metabolic syndrome in children with psoriatic disease. 2013 , 30, 700-5		37

505	Biological therapies for psoriasis. 2013 , 13, 1715-30		19
504	The role of nutrition in dermatologic diseases: facts and controversies. 2013 , 31, 677-700		25
503	Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. 2013 , 305, 891-7		11
502	Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 523-9	4.5	63
501	Platelet activation: a link between psoriasis per se and subclinical atherosclerosis--a case-control study. 2013 , 169, 68-75		36
500	Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. 2013 , 169, 783-93		92
499	Adherence to medication in patients with psoriasis: a systematic literature review. 2013 , 168, 20-31		109
498	Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1387-404	4.6	86
497	Association between obesity measured by different parameters and severity of psoriasis. 2013 , 52, 177-81		36
496	Skin Health and Metabolic Complications. 2013 , 39-47		3
495	Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. 2013 , 168, 2282-8		29
494	Psoriasis y su relaci3n con el s3ndrome metab3lico. 2013 , 20, 228-236		1
493	Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. 2013 , 99, 936-42		17
492	Eficacia y seguridad en terapia con psoralen-UVA (PUVA) t3pica en psoriasis palmoplantar. Experiencia en una serie de 48 pacientes. 2013 , 104, 418-425		8
491	Cardiovascular aspects of psoriasis: an updated review. 2013 , 52, 153-62		39
490	Can treatment of the skin rescue the heart?. 2013 , 273, 186-8		
489	Inflammation, atherosclerosis, and psoriasis. 2013 , 44, 194-204		68
488	Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. 2013 , 149, 166-76		118

487	Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. 2013 , 149, 84-91		205
486	Obesity, waist circumference, weight change and the risk of psoriasis in US women. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1293-8	4.6	64
485	Association between osteoporosis and psoriasis: results from the Longitudinal Health Insurance Database in Taiwan. 2013 , 24, 1835-41		32
484	Cumulative life course impairment: evidence for psoriasis. 2013 , 44, 82-90		27
483	Psoriatic arthritis and diabetes: a population-based cross-sectional study. 2013 , 2013, 580404		19
482	Psoriasis and Cardiovascular Risk: Assessment by CUORE Project Risk Score in Italian Patients. 2013 , 2013, 389031		8
481	The effect of weight loss in obese patients with chronic stable plaque-type psoriasis. 2013 , 2013, 795932		15
480	Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. 2013 , 17, 89-105		6
479	Comorbidities in psoriasis. 2013 , 79 Suppl 7, S10-7		16
478	The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. 2013 , 31, 433-42; discussion 442-3		137
477	Psoriasis and new-onset diabetes: a Danish nationwide cohort study. 2013 , 36, 2402-7		57
476	Effect of weight loss on the severity of psoriasis: a randomized clinical study. 2013 , 149, 795-801		134
475	Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. 2013 , 149, 717-21		28
474	Comorbidities of psoriasis. 2013 , 8, 277-290		1
473	Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. 2013 , 273, 273-82		48
472	Long-term safety of biologics in the treatment of psoriasis. <i>Psoriasis: Targets and Therapy</i> , 2013 , 1	2.4	2
471	Co-morbidities in psoriasis: a hospital-based case-control study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1417-25	4.6	14
470	Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting. 2013 , 40, 1434-7		19

469	The association between psoriasis and dyslipidaemia: a systematic review. 2013 , 168, 486-95	108
468	Future diagnosis, today's treatment - cardiomyopathy in the course of psoriasis: a case report. 2013 , 26, 489-92	6
467	Do patients with mild to moderate psoriasis really have a sedentary lifestyle?. 2013 , 52, 1129-34	13
466	Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study. 2013 , 16, 667-73	18
465	Cumulative life course impairment: identifying patients at risk. 2013 , 44, 74-81	12
464	Metabolisches Syndrom bei unbehandelten Psoriasispatienten: eine Fall-Kontroll-Studie. 2013 , 11, 1169-1176	
463	The Association of Psoriasis and Elevated Blood Lipids in Overweight and Obese Children. 2013 , 2013, 36-38	
462	Recognition of Tuberous Sclerosis in Adult Women: Delayed Presentation With Life-Threatening Consequences. 2013 , 2013, 38-40	1
461	Metabolic syndrome in untreated patients with psoriasis: case-control study. 2013 , 11, 1169-75	13
460	Antihypertensive Drugs and Psoriasis. 2013 , 19a, 110-113	
459	Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. 2013 , 2013, 901215	19
458	Psoriasis □Types, Causes and Medication. 2013 ,	1
457	Years of Work Results in Win: D.C. Releases First-Ever Psoriasis Public Health Agenda. 2013 , 19a, 84-88	
456	Quality of Life in Psoriasis. 2013 ,	1
455	Comorbidities and cardiovascular risk factors in patients with psoriasis. 2014 , 89, 735-44	32
454	Serum leptin and adiponectin levels in Korean patients with psoriasis. 2014 , 29, 729-34	18
453	Editorial: Modifying Cardiovascular Risk Factors: Newer Advances in Cardiovascular Metabolism and Diagnostic Technologies. 2014 , 20, 6073-7	
452	Lipid profile and metabolic syndrome status in patients with oral lichen planus, oral lichenoid reaction and healthy individuals attending a dental college in northern India - a descriptive study. 2014 , 8, ZC92-5	14

451	Metabolic syndrome and its components in patients with psoriasis. 2014 , 3, 612		16
450	Psoriasis as a risk factor of cardiovascular diseases. 2014 , 6, 500-506		2
449	Metabolic changes and serum ghrelin level in patients with psoriasis. 2014 , 2014, 175693		5
448	Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. 2014 , 5, 368		55
447	A combinational therapy for patients with severe psoriasis associated with cardiovascular disease. 2014 , 64, 613-6		
446	Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. 2014 , 65, 74-8		58
445	Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1380-7	4.6	6
444	Effect of the FTO rs9930506 polymorphism on obesity and the main clinical outcomes in patients with psoriasis. 2014 , 171, 917-9		7
443	Psoriasis and comorbidities in a southern Brazilian population: a case-control study. 2014 , 53, e518-25		14
442	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). 2014 , 171, 137-47		89
441	Psoriasis and smoking: a systematic review and meta-analysis. 2014 , 170, 304-14		137
440	High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 592-595	4.3	11
439	Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 907-14	4.6	47
438	Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy. 2014 , 171, 436-8		12
437	Patients with psoriasis have an increased amount of epicardial fat tissue. 2014 , 39, 123-8		16
436	Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1235-44	4.6	16
435	Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients. 2014 , 306, 921-5		19
434	Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. 2014 , 24, 662-9		3

433	Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada. 2014 , 18, 371-8		13
432	Role of E-cadherin in psoriasis. 2014 , 34, 148-154		1
431	Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1661-9	4.6	31
430	Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis. 2014 , 42, 386-94		18
429	Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. 2014 , 66, 304-10		51
428	Traditional Systemic Therapy I: Methotrexate and Cyclosporine. 2014 , 117-130		
427	Hypertension, antihypertensive medication use, and risk of psoriasis. 2014 , 150, 957-63		49
426	Psoriasis and comorbidities: links and risks. 2014 , 7, 119-32		85
425	Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. 2014 , 171, 1561-5		52
424	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 333-7	4.6	134
423	Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 1067-75	4.5	25
422	No association between psoriasis and diabetes in the U.S. population. 2014 , 104, e58-60		4
421	Managing moderate-to-severe psoriasis in the elderly. 2014 , 31, 233-8		39
420	Does treatment of psoriasis reduce the risk of cardiovascular disease?. 2014 , 74, 169-82		15
419	Obesity and Psoriasis: Inflammatory Nature of Obesity, Relationship Between Psoriasis and Obesity, and Therapeutic Implications. 2014 , 105, 31-44		7
418	Anti-psoriatic therapy recovers high-density lipoprotein composition and function. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 635-642	4.3	56
417	Psoriasis as a systemic disease. 2014 , 32, 343-50		93
416	From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 168-77	4.5	107

415	Research gaps in psoriasis: opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 146-67	4.5	85
414	Increased prevalence of psoriasis in patients with coronary artery disease: results from a case-control study. 2014 , 171, 580-7		13
413	Molecular Diagnostics in Dermatology and Dermatopathology. Michael J. Murphy, ed. New York: Springer, 2011; 478 pp. ISBN: 978-1-60761-171-4. Price £213.00.. 2014 , 171, 919-920		
412	IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease. 2014 , 105 Suppl 1, 21-33		14
411	Inflammatory markers of cardiovascular disease risk in Portuguese psoriatic patients: relation with narrow-band ultraviolet B and psoralen plus ultraviolet A. 2014 , 53, 393-6		4
410	Cardiovascular comorbidities in childhood psoriasis. 2014 , 24, 229-35		20
409	Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. 2014 , 24, 305-11		24
408	Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. 2014 , 25, 470-81		13
407	Increased subclinical atherosclerosis in patients with chronic plaque psoriasis. 2014 , 237, 499-503		16
406	Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease. 2014 , 41, 981-5		18
405	The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. 2014 , 14, 749-56		79
404	Advances in Psoriasis. 2014 ,		3
403	Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. 2014 , 1841, 1709-15		26
402	The economic burden of psoriasis: a systematic literature review. 2014 , 14, 685-705		43
401	HLA-C*12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. 2014 , 41, 697-704		25
400	Treating moderate to severe psoriasis - best use of biologics. 2014 , 10, 269-79		23
399	Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). 2014 , 306, 667-76		17
398	The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. 2014 , 5, 9-19		60

397	Hemagglutination during photopheresis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, e61-2	4-5	1
396	Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. 2014 , 105, 31-44		74
395	Cardiovascular risk and psoriasis: beyond the traditional risk factors. 2014 , 127, 12-8		53
394	Management of psoriasis vulgaris and multiple sclerosis with fumaric acid. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, e60-1	4-5	6
393	Neuronatin is related to keratinocyte differentiation by up-regulating involucrin. 2014 , 73, 225-31		7
392	Bariatric surgery and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 774-779	4-5	15
391	Assessment of atrial electromechanical delay and P-wave dispersion in patients with psoriasis. 2014 , 31, 1071-6		12
390	Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. 2014 , 47, 37-45		127
389	Aiming for remission in psoriatic arthritis. 2014 , 9, 147-153		1
388	Vitamin D3 levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis. 2015 , 42, 679-84		23
387	Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study. 2015 , 42, 1042-52		20
386	Frequency and characteristics of circulating CD4(+) CD28(null) T cells in patients with psoriasis. 2015 , 173, 998-1005		9
385	The heartbreak of psoriasis: a review of cardiovascular risk in patients with psoriasis. 2015 , 23, 312-6		13
384	Impact of antipsoriatic therapy on endothelial function. 2015 , 173, 1440-6		3
383	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. 2015 , 173, 510-8		67
382	The positive impact of the new National Institute for Health and Care Excellence lipid guidelines on cardiovascular disease risk management in patients with psoriasis. 2015 , 173, 1327-8		
381	Assessment of serum levels of osteopontin, selenium and prolactin in patients with psoriasis compared with healthy controls, and their association with psoriasis severity. 2015 , 40, 741-6		11
380	Identifying Performance Gaps in Comorbidity and Risk Factor Screening, Prevention, and Counseling Behaviors of Providers Caring for Children with Psoriasis. 2015 , 32, 813-8		3

379	Non-alcoholic fatty liver disease and psoriasis: So far, so near. 2015 , 7, 315-26		45
378	Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. 2015 , 21, 874-88		34
377	A study of awareness and screening behavior of cardiovascular risk factors in patients with psoriasis and dermatologists. 2015 , 27, 59-65		4
376	1966 to the Present: The Impact of the National Psoriasis Foundation. 2015 , 21a, 63-67		
375	Links and risks associated with psoriasis and metabolic syndrome. <i>Psoriasis: Targets and Therapy</i> , 2015 , 5, 125-128	2.4	7
374	Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. 2015 , 32, 290-5		18
373	Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. 2015 , 21, 201-9		50
372	Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice. 2015 , 10, e0126599		57
371	Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications. 2015 , 10, e0132454		15
370	Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. 2015 , 151, 161-9		60
369	Psoriasis and metabolic syndrome. 2015 , 69, 85-7		38
368	Psoriasis vulgaris with or without arthritis and independent of disease severity or duration is a risk factor for hypercholesterolemia. 2015 , 230, 170-6		4
367	Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. 2015 , 26, 318-25		10
366	Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. 2015 , 6, 43-54		15
365	Anti-TNF- α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1325-30	4.6	51
364	Obesity and the metabolic syndrome in pediatric psoriasis. 2015 , 33, 305-15		28
363	Association between psoriasis, diabetes mellitus, hypertension and obesity. 2015 , 3, 132-136		
362	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1156-63	4.6	19

361	Psoriasis, Cardiovascular Risk, and Antihypertensive Drugs.. 2015 , 9, 563-568		
360	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 410-9.e6	4.5	49
359	Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2955-2963	4.3	67
358	Reactive oxygen species in psoriasis and psoriasis arthritis: relevance to human disease. 2015 , 166, 135-49		9
357	Psoriasis and polycystic ovary syndrome: a new link in different phenotypes. 2015 , 191, 101-5		3
356	IL-17 and Its Receptor System: a New Target for Psoriatic Arthritis. 2015 , 1, 210-220		1
355	The Relationship of Obesity With the Severity of Psoriasis: A Systematic Review. 2015 , 19, 450-6		50
354	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2189-2197	4.3	96
353	Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor- α inhibitors: results of a retrospective analysis. 2015 , 54, 839-45		44
352	Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin-17 and interleukin-22 production in mice. 2015 , 24, 436-42		37
351	Economic Burden of Psoriasis in the United States: A Systematic Review. 2015 , 151, 651-8		144
350	Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis. 2015 , 41, 581-91		16
349	The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. 2015 , 15, 877-84		5
348	Survey of trends and gaps in dermatologists' cardiovascular screening practices in psoriasis patients: Areas still in need of improvement. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 872-4.e4	4.5	9
347	Increased urinary albumin/creatinine ratio is associated with atopic dermatitis in Korean males: The 2011-2013 Korea National Health and Nutrition Examination Survey. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 874-6	4.5	2
346	Impacto de la obesidad y de la dieta en la psoriasis. 2015 , 30, 437-442		
345	Prevalence of Metabolic Syndrome in Patients with Mucosal Lichen Planus: A Case-Control Study. 2015 , 16, 439-45		24
344	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. 2015 , 42, 1767-80		88

343	Influence of psoriasis on circulatory system function assessed in echocardiography. 2015 , 307, 855-61		10
342	Psoriasis and cardiovascular risk assessment in primary care. 2015 , 65, 476		
341	Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 955-63	4.6	63
340	Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?. 2015 , 400, 207-12		25
339	Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. 2015 , 67, 708-17		39
338	Association of chronic periodontitis and psoriasis: periodontal status with severity of psoriasis. 2015 , 21, 314-9		25
337	Association between antidiabetic drugs and psoriasis risk in diabetic patients: results from a nationwide nested case-control study in Taiwan. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 123-30	4.5	29
336	Psoriasis and the life cycle of persistent life effects. 2015 , 33, 25-39		23
335	Ten years on: the impact of biologics on the practice of dermatology. 2015 , 33, 111-25		14
334	Psoriasis and sport: a new ally?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 515-20	4.6	28
333	Clinico-biochemical correlation between psoriasis and insulin resistance. 2015 , 30, 99-103		6
332	Assessment of arterial stiffness and cardiovascular hemodynamics by oscillometric method in psoriasis patients with normal cardiac functions. 2015 , 30, 347-54		22
331	Underdiagnosis of Cardiovascular Risk Factors in Outpatients with Psoriasis Followed at Hospital Dermatology Offices: The PSO-RISK Study. 2016 , 96, 972-973		2
330	Prevalence and related factors of psoriasis and seborrheic dermatitis: a community-based study. 2016 , 46, 303-9		2
329	Psoriasis comorbidities: complications and benefits of immunobiological treatment. 2016 , 91, 781-789		21
328	Hormonal Factors and Risk of Psoriasis in Women: A Cohort Study. 2016 , 96, 927-931		8
327	Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. 2016 , 8, 120-31		33
326	Epicardial fat tissue in patients with psoriasis:a systematic review and meta-analysis. 2016 , 15, 103		21

325	Diagnosis and underdiagnosis of comorbidities in psoriasis patients - need for a multidisciplinary approach. 2016 , 91, 743-747		3
324	Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis. 2016 , 95, e3676		35
323	Psoriasis Trends and Practice Gaps. 2016 , 34, 235-42		6
322	Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan. 2016 , 25, 133-40		20
321	Metabolic syndrome in Moroccan patients with psoriasis. 2016 , 55, 396-400		15
320	Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1742-1748	4.6	7
319	Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). 2016 , 16, 12		28
318	Terminalia Chebulanin Attenuates Psoriatic Skin Lesion via Regulation of Heme Oxygenase-1. 2016 , 39, 531-43		20
317	Psoriasis and Obesity. 2016 , 232, 633-639		94
316	Evolution of primary care databases in UK: a scientometric analysis of research output. 2016 , 6, e012785		31
315	The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 2173-2182	4.3	27
314	Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. 2016 , 251, 25-30		35
313	Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. 2016 , 17, 29		8
312	A multileveled approach in psoriasis assessment and follow-up: A proposal for a tailored guide for the dermatological practice. 2016 , 27, 298-310		6
311	Cognitive Impairment in Patients with Psoriasis: A Cross-Sectional Study Using the Montreal Cognitive Assessment. 2016 , 17, 413-9		21
310	Amentoflavone protects against psoriasis-like skin lesion through suppression of NF- κ B-mediated inflammation and keratinocyte proliferation. 2016 , 413, 87-95		30
309	Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity. 2016 , 152, 761-7		49
308	SnapshotDx Quiz: October 2016. <i>Journal of Investigative Dermatology</i> , 2016 , 136, e105	4.3	

307	Cardiovascular Disease Outcomes Associated with Three Major Inflammatory Dermatologic Diseases: A Propensity-Matched Case Control Study. 2016 , 6, 649-658	22
306	Kidney Disease and Psoriasis. A New Comorbidity?. 2016 , 107, 823-829	5
305	GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. 2016 , 119, 1242-1253	71
304	Analysis of telomere length as predictive marker in psoriasis for comorbidities. 2016 , 25, 388-90	2
303	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 897-905	4-5 32
302	Neutrophil extracellular trap formation is increased in psoriasis and induces human α -defensin-2 production in epidermal keratinocytes. 2016 , 6, 31119	88
301	Considerations for Systemic Treatment of Psoriasis in Obese Patients. 2016 , 17, 609-615	29
300	Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study. 2016 , 44, 43-47	2
299	Kidney Disease and Psoriasis. A New Comorbidity?. 2016 , 107, 823-829	2
298	Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. 2016 , 8, 330ra37	96
297	Primary care-based screening for cardiovascular risk factors in patients with psoriasis. 2016 , 175, 348-56	19
296	Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. 2016 , 12, 1299-1308	47
295	Carotid intima-media thickness, nonalcoholic fatty liver disease, and hemoglobin A1c are independently associated with the severity of psoriasis. 2016 , 34, 135-140	2
294	Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: a prospective observational follow-up study. 2016 , 104, 259-65	41
293	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. 2016 , 6, 151-67	4
292	Los 10 diagn3sticos m3s frecuentes en dermatolog3a. 2016 , 23, 119-141	
291	Rhumatisme psoriasique et ob3sité. 2016 , 83, 34-36	
290	Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis Severity. 2016 , 20, 221-7	37

289	[New populations at increased cardiovascular risk: Cardiovascular disease in dermatological diseases]. 2016 , 28, 143-53	2
288	Erectile dysfunction in patients with plaque psoriasis: the relation of depression and cardiovascular factors. 2016 , 28, 96-100	20
287	Chemical profiling and anti-psoriatic activity of methanolic extract of <i>Andrographis nallamalayana</i> J.L.Ellis. 2016 , 30, 1256-61	12
286	Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 161-172	4-3 36
285	Psoriasis as an Independent Risk Factor for Cardiovascular Disease: An Epidemiologic Analysis Using a National Database. 2016 , 20, 327-33	29
284	Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis. 2016 , 55, 52-9	14
283	Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. 2017 , 37, 97-105	36
282	Development of an algorithm for determining smoking status and behaviour over the life course from UK electronic primary care records. 2017 , 17, 2	14
281	Psoriasis and cardiovascular events: updating the evidence. 2017 , 309, 225-228	26
280	Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. 2017 , 56, 428-434	12
279	Interleukin 17A and Toll-like Receptor 4 in Patients with Arterial Hypertension. 2017 , 42, 99-108	7
278	Endocrine Comorbidities in Patients with Psoriatic Arthritis: A Population-based Case-controlled Study. 2017 , 44, 786-790	9
277	"Inflammatory skin march" in atopic dermatitis and psoriasis. 2017 , 66, 833-842	51
276	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. 2017 , 390, 276-288	302
275	Imiquimod induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipidaemia comorbidity. 2017 , 88, 20-28	9
274	Pediatric Psoriasis. 2017 , 18, 797-811	23
273	Hydrogen sulfide alleviates hypertensive kidney dysfunction through an epigenetic mechanism. 2017 , 312, H874-H885	36
272	Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan. 2017 , 28, 613-622	

271	Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. 2017 , 6, 322-330		10
270	Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. 2017 , 69, 1510-1518		73
269	Bone mineral density is lower in male than female patients with plaque-type psoriasis in Iran. 2017 , 3, 201-205		8
268	The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 650-656.e3	4-5	48
267	Psoriasis. 2017 , 81-124		3
266	Pro-oxidant status and Nrf2 levels in psoriasis vulgaris skin tissues and dimethyl fumarate-treated HaCaT cells. 2017 , 40, 1105-1116		20
265	Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 1038-1046	4-5	22
264	Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. 2017 , 8, 737-746		15
263	Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. 2017 , 34, 583-588		8
262	Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. 2017 , 56, 1103-1118		29
261	Smoking and risk of psoriasis: A nationwide cohort study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 573-575	4-5	22
260	Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: A case-control study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 575-577	4-5	5
259	Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. 2017 , 19, 102		66
258	Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. 2017 , 11, 1243-1256		33
257	Exploring the link between cadmium and psoriasis in a nationally representative sample. 2017 , 7, 1723		16
256	Co-morbidity in psoriasis: mechanisms and implications for treatment. 2017 , 13, 27-34		19
255	Psoriasis and Other Skin Inflammatory Diseases. 2017 , 1091-1104		1
254	Levels of osteopontin in plasma and tissue in relation to metabolic status in patients with lichen planus. 2017 , 14, 173-178		1

253	Immune System Links Psoriasis-Mediated Inflammation to Cardiovascular Diseases via Traditional and Non-Traditional Cardiovascular Risk Factors. 2017 ,	1
252	Unerwünschte Wirkungen von Biologika bei Psoriasis. 2017 , 5, 195-199	0
251	Homocysteine: A Potential Common Route for Cardiovascular Risk and DNA Methylation in Psoriasis. 2017 , 130, 1980-1986	12
250	Cardiac Immunomodulation. 2017 , 681-714	1
249	Systemic Inflammation, Oxidative Damage to Nucleic Acids, and Metabolic Syndrome in the Pathogenesis of Psoriasis. 2017 , 18,	28
248	Old and New Biological Therapies for Psoriasis. 2017 , 18,	125
247	Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis. 2017 , 18,	52
246	Psoriasis and Cardiovascular Risk-Do Promising New Biomarkers Have Clinical Impact?. 2017 , 2017, 7279818	9
245	Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. 2017 , 56, 1613-1619	39
244	MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1 β and VEGFA: Implications for psoriasis treatment. 2017 , 12, e0175459	25
243	Psoriasis-associated vascular disease: the role of HDL. 2017 , 24, 73	10
242	The Role of Methotrexate in Psoriatic Therapy in the Age of Biologic and Biosimilar Medication: Therapeutic Benefits versus Toxicology Emergencies. 2017 ,	1
241	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. 2017 , 92, 46-51	32
240	The role of lipids in psoriasis. 2017 , 104, 619-635	7
239	Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis. 2018 , 7, 37-42	3
238	Transplantation of skin mesenchymal stem cells attenuated AngII-induced hypertension and vascular injury. 2018 , 497, 1068-1075	3
237	Association of the novel susceptible locus rs9266150 with clinical features of psoriasis vulgaris in the Chinese Han population. 2018 , 27, 748-753	1
236	Prevalence of metabolic syndrome in children with moderate to severe psoriasis treated with TNF inhibitors in comparison to conventional agents. 2018 , 31, e12566	2

235	Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. 2018 , 9, 5-21			83
234	Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients. 2017 , 20, 1			17
233	A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. 2018 , 179, 173-181			38
232	Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients. 2018 , 10, 9			41
231	The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study. 2018 , 29, 3-7			10
230	Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. 2018 , 27, 409-417			92
229	Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. 2018 , 55, 254-270			1
228	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 323-332	4.5		47
227	The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 54-61.e15	4.5		51
226	Adverse Reactions to Biologics in Psoriasis. 2018 , 53, 1-14			11
225	Psoriasis improvement after gastric bandage in a patient partial responder to infliximab. 2018 , 31, e12584			
224	A study of ACE, eNOS and MTHFR association with psoriasis in Pakistani population. 2018 , 15, 65-69			2
223	The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. 2018 , 14, 1-19			15
222	Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. 2018 , 13, 199-209			15
221	Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship. 2018 , 10, e2195			18
220	Psoriasis and sexual dysfunction: links, risks, and management challenges. <i>Psoriasis: Targets and Therapy</i> , 2018 , 8, 93-99	2.4		3
219	Clinical and Genetic Heterogeneity of Mutations in Psoriatic Skin Disease. 2018 , 9, 2239			30
218	Sociodemographic variables, health-related behaviors, and disease characteristics in patients with psoriasis. 2018 , 20, 149-153			0

217	Metabolic syndrome, C-reactive protein and cardiovascular risk in psoriasis patients: a cross-sectional study. 2018 , 93, 222-228	9
216	Hypertension: Focus on autoimmunity and oxidative stress. 2018 , 125, 104-115	62
215	Psoriasis in Taiwan: From epidemiology to new treatments. 2018 , 36, 115-123	28
214	Young patients with risk factors prevalent in the elderly - differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers. 2018 , 10, 705-715	5
213	Potential Immunological Links Between Psoriasis and Cardiovascular Disease. 2018 , 9, 1234	31
212	Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. 2018 , 93, 205-211	19
211	Psoriasis: Psychosomatic, somatopsychic, or both?. 2018 , 36, 698-703	10
210	Serum homocysteine, folate and vitamin B levels in patients with psoriasis: a systematic review and meta-analysis. 2019 , 180, 382-389	11
209	An Update on the Role of Adipose Tissues in Psoriasis. 2019 , 10, 1507	27
208	Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. 2019 , 11, 143-156	6
207	Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk. 2019 , 60, e304-e310	4
206	Electronic Health Record Databases. 2019 , 241-289	2
205	Evaluation of Psoriasis Patients. 2019 ,	
204	Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy. 2019 , 11, 11-16	4
203	Evaluation of plasma levels of tissue factor and tissue factor pathway inhibitor in patients with psoriasis. 2019 , 36, 442-448	1
202	Psoriasis: Past, Present, and Future. <i>Journal of Investigative Dermatology</i> , 2019 , 139, e133-e142	4-3 15
201	Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: A 15-year nationwide population-based cohort study. 2019 , 46, 859-866	13
200	Coronary Artery Disease Assessed by Computed Tomography in Patients with Psoriasis: A Systematic Review and Meta-Analysis. 2019 , 235, 478-487	14

199	Risk Factors for the Development of Psoriasis. 2019 , 20,	93
198	Association between Psoriasis and Obesity. 2019 , 16, 58-61	
197	Skin disease related to metabolic syndrome in women. 2019 , 5, 205-212	6
196	Efficacy of Calcipotriol-Betamethasone Ointment in Patients with Mild to Moderate Plaque Psoriasis: Subgroup Analyses. 2019 , 235, 501-508	3
195	New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. 2019 , 18, 171	34
194	The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. 2019 , 13, 1405-1412	17
193	Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. 2019 , 36, 691-707	5
192	Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. 2019 , 94, 76-107	13
191	Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?. 2019 , 2019, 3159283	44
190	Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies. 2019 , 6, 49	76
189	FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt/GSK-3 β /catenin signalling via FGFR4. 2019 , 46, 761-769	8
188	Psoriasis in obesity: comparison of serum levels of leptin and adiponectin in obese subjects - cases and controls. 2019 , 94, 192-197	8
187	Serum homocysteine level, vitamin B12 levels, and erythrocyte folate in psoriasis: A case-control study. 2019 , 5, 171-174	7
186	Malondialdehyde, lipoprotein-a, lipoprotein ratios, comprehensive lipid tetrad index and atherogenic index as surrogate markers for cardiovascular disease in patients with psoriasis: a case-control study. 2019 , 311, 287-297	14
185	The pharmacological management of patients with comorbid psoriasis and obesity. 2019 , 20, 863-872	16
184	The Influence of FTO Polymorphism rs9939609 on Obesity, Some Clinical Features, and Disturbance of Carbohydrate Metabolism in Patients with Psoriasis. 2019 , 2019, 7304345	10
183	Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters. 2019 , 49, 110-115	1
182	Subclinical atherosclerosis in psoriasis. Usefulness of femoral artery ultrasound for the diagnosis, and analysis of its relationship with insulin resistance. 2019 , 14, e0211808	13

181	Treating to Target(s) With Interleukin-17 Inhibitors. 2019 , 23, 3S-34S	3
180	Psorijaza Ævidljivi ubojica. 2019 , 55, 215-223	
179	Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. 2019 , 7, e000725	19
178	Risk of End-Stage Renal Disease in Psoriatic Patients: Real-World Data from a Nationwide Population-Based Cohort Study. 2019 , 9, 16581	7
177	Metabolic syndrome and inflammatory skin conditions. 2019 , 31, 515-522	2
176	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. 2019 , 58, 144-148	15
175	Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. 2019 , 22, 269-274	5
174	Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update. 2019 , 23, 3S-12S	13
173	Factors associated with successful switching between biologic therapies for the treatment of psoriasis in daily dermatological real-life practice: The Resoswitch study. 2019 , 32, e12789	2
172	Tissue lipocalin-2 in psoriasis: is it a marker of metabolic disturbance or a possible marker of therapeutic efficacy after narrow band ultraviolet B?. 2020 , 31, 519-523	4
171	Biological therapy for pustular psoriasis: a systematic review. 2020 , 59, 284-296	10
170	Antibodies towards high-density lipoprotein components in patients with psoriasis. 2020 , 312, 93-102	2
169	Phototherapy decreases red blood cell deformability in patients with psoriasis. 2019 , 73, 489-496	2
168	Editorial commentary: Psoriasis, inflammation and cardiometabolic disease. Will we ever get to the heart of the matter?. 2020 , 30, 479-480	1
167	Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. 2020 , 5, 129-138	0
166	Retrospective analysis of patients with psoriasis receiving biological therapy: Real-life data. 2020 , 33, e14336	2
165	Curcumin attenuates autoimmunity and renal injury in an experimental model of systemic lupus erythematosus. 2020 , 8, e14501	5
164	Effect of Excessive Body Weight and Psoriasis in Women Undergoing ICSI Procedure and State of Health of the Newborn. 2020 , 9,	0

163	The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study. 2020 , 12, 737-744	1
162	Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents. 2020 , 1-14	2
161	A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis. 2020 , 10, 1121-1135	1
160	Blood pressure and albuminuria in a female mouse model of systemic lupus erythematosus: impact of long-term high salt consumption. 2020 , 319, R448-R454	2
159	Impact of Psoriasis on Mortality Rate and Outcome in Myocardial Infarction. 2020 , 9, e016956	7
158	Factors Associated with Increased Morbidity and Mortality of Obese and Overweight COVID-19 Patients. 2020 , 9,	13
157	Long-Term and Clinically Relevant Full-Thickness Human Skin Equivalent for Psoriasis.. 2020 , 3, 6639-6647	3
156	Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. 2021 , 60, 2816-2825	3
155	IL-17A in the Psoriatic Patients' Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity. 2020 , 2020, 7420823	5
154	Quantifying the Effect of Supplementation with Algae and Its Extracts on Glycolipid Metabolism: A Meta-Analysis of Randomized Controlled Trials. 2020 , 12,	4
153	Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus. 2020 , 318, F1074-F1085	2
152	Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report. 2020 , 20, 106	1
151	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. 2019 , 10, 3096	46
150	Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials. 2020 , 133, 444-451	3
149	A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. 2020 , 99, e19303	14
148	Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis. 2020 , 11, 1047-1055	9
147	The Roles of Lipoprotein in Psoriasis. 2020 , 21,	13
146	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 123-134 ^{4.6}	12

145	Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis. 2021 , 313, 163-171	3
144	Innate Immune Mechanisms of Arterial Hypertension and Autoimmune Disease. 2021 , 34, 143-153	1
143	Dietary and Lifestyle Cardiometabolic Risk Reduction Strategies in Pro-inflammatory Diseases. 2021 , 179-191	
142	Cardiovascular Diseases and Rheumatology. 2021 , 353-381	
141	Skin and metabolic syndrome: A review of the possible associations. 2021 , 26, 16	0
140	Additional effect of excimer light therapy in patients with psoriasis under other therapies. 2021 , 48, 911-915	0
139	Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges. 2021 , 22, 293-300	1
138	Optimal biologic dosing in management of obese patients with psoriasis. 2021 , 87, 424-426	0
137	Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study. 2021 , 8, 629741	1
136	Association of inflammatory disease and long-term outcomes among young adults with myocardial infarction: the Mass General Brigham YOUNG-MI Registry. 2021 ,	2
135	Psoriasis: Comorbidities. 2021 , 48, 732-740	10
134	Psoriasis does not worsen outcomes in patients admitted for ischemic stroke: an analysis of the National Inpatient Sample. 2021 , 69, 994-998	
133	Use of primary care services among patients with chronic skin disease seen by dermatologists. 2021 , 2, 31-36	5
132	Next-generation sequencing of the whole mitochondrial genome identifies novel and common variants in patients with psoriasis, type 2 diabetes mellitus and psoriasis with comorbid type 2 diabetes mellitus. 2021 , 14, 41	0
131	Psoriasis Severity and Cardiometabolic Risk Factors in a Representative US National Study. 2021 , 22, 719-730	0
130	Psoriasis und nichtalkoholische Fettleber. 2021 , 19, 503-504	
129	Psoriasis and non-alcoholic fatty liver disease. 2021 , 19, 503-504	3
128	Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1329-1338	4.5 8

127	Risk of psoriasis according to body mass index: A retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	7
126	High serum level of interleukin-6 is linked with dyslipidemia in oral lichen planus. 2021 , 22, 987		3
125	Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	10
124	Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health. <i>Psoriasis: Targets and Therapy</i> , 2021 , 11, 99-108	2.4	0
123	Gout Augments the Risk of Cardiovascular Disease in Patients With Psoriasis: A Population-Based Cohort Study. 2021 , 12, 703119		2
122	Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity. <i>Journal of Investigative Dermatology</i> , 2021 ,	4.3	2
121	Prevalence and Extent of Subclinical Atherosclerosis and Associated Cardiovascular Risk Factors in Adult Patients With Psoriatic Arthritis: A Systematic Review. 2021 , 13, e16853		1
120	Systematic review with meta-analysis: autoimmune hepatitis in pregnancy. 2021 , 56, 1194-1204		2
119	Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. 2021 , 41, 917-925		7
118	Psoriasis and Cardiovascular Disease: A Narrative Review. 2021 , 42, 345-355		4
117	Association between atopic dermatitis and hypertension: a systematic review and meta-analysis. 2021 ,		1
116	New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2328-2337	4.3	4
115	Abdominal subcutaneous adipose tissue negatively associates with subclinical coronary artery disease in men with psoriasis. 2021 , 8, 100231		
114	First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq. 2021 , 237, 338-346		0
113	Medical Record Databases. 224-243		22
112	Psoriasis: Epidemiology, Potential Triggers, Disease Course. 2014 , 27-37		1
111	Psoriasis. 2009 , 506-526		9
110	Autoimmune Disease-Associated Hypertension. 2019 , 21, 10		19

109	Psoriasis and daily low-emission phototherapy: effects on disease and vitamin D level. 2015 , 31, 83-9	7
108	Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time. 2020 , 5,	7
107	Psoriasis and hypertension severity: results from a case-control study. 2011 , 6, e18227	59
106	Increased prevalence of metabolic syndrome in patients with acne inversa. 2012 , 7, e31810	136
105	Association of carotid intima-media thickness with leptin and apolipoprotein b/apolipoprotein a-I ratio reveals imminent predictors of subclinical atherosclerosis in psoriasis patients. 2014 , 57, 21-7	12
104	Age and gender differences in Framingham risk score and metabolic syndrome in psoriasis patients: A cross-sectional study in the Turkish population. 2017 , 17, 66-72	6
103	Psoriasis Comorbidities in Childhood. 2020 , 19, 460-467	4
102	Heart rate variability in patients with psoriatic arthritis: associations with systemic inflammation and traditional cardiovascular risk factors. 2011 , 10, 88-92	1
101	Quality of life of patients with psoriasis. 2020 , 28, 219-225	1
100	Cardiovascular Consequences of Autoimmune Rheumatic Diseases. 2020 , 18, 566-579	1
99	The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. 2020 , 20, 703-717	15
98	A study of the prevalence of diabetes, insulin resistance, lipid abnormalities, and cardiovascular risk factors in patients with chronic plaque psoriasis. 2011 , 56, 520-6	31
97	Psoriasis and increased prevalence of hypertension and diabetes mellitus. 2011 , 56, 533-6	34
96	Cardiovascular comorbidity in psoriasis. 2011 , 56, 553-6	6
95	Dyslipidemia in Dermatological Disorders. 2015 , 7, 421-8	24
94	Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. 2015 , 6, 322-5	31
93	Assessment of the Possible Role of FOXP3 Gene (rs3761548) Polymorphism in Psoriasis Vulgaris Susceptibility and Pathogenesis: Egyptian Study. 2019 , 10, 401-405	5
92	Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort). 2017 , 21, 581-587	11

91	Association of endothelial nitric oxide synthase Glu298Asp gene polymorphism in psoriasis cases with hypertension. 2014 , 34, 340-5	5
90	Psoriasis and high blood pressure. 2015 , 69, 13-5	7
89	Double trouble: psoriasis and cardiometabolic disorders. 2018 , 29, 189-194	3
88	Increased P-wave dispersion in patients with newly diagnosed lichen planus. 2013 , 68, 846-50	14
87	Psoriasis and insulin resistance: a review. 2014 , 3, 3	5
86	Atherosclerosis attacks in patients with psoriasis vulgaris but without a relationship with the severity and course of the disease. 2021 , 38, 673-681	0
85	RELATION OF ELEVATED SERUM LIPIDS AND LIPOPROTEIN (A) TO OXIDATIVE STRESS IN PSORIASIS.. 2021 , 39-41	
84	The Metabolic Syndrome. 2009 , 423-445	
83	PsoriasisNeues Verständnis einer alten Erkrankung. 2009 , 175-179	
82	Papulosquamous disorders. 2009 , 183-195	
81	Cardiovascular Risk and Prevention in Rheumatic Diseases. 2010 , 1200-1204.e2	
80	The Role of Cardiovascular Disease in the Patient with Psoriasis. 2011 , 17a, 42-55	
79	JUSTIFICACI DE LA IMPORTANCIA DE VALORAR EL RIESGO CARDIOVASCULAR EN PSORIASIS. 2012 , 1-27	
78	The Association Between Psoriasis and Cardiovascular Diseases. 2013 , 10,	1
77	Cardiovascular and Metabolic Comorbidities in Patients with Plaque-Type Psoriasis Never Treated with Systemic Antipsoriatic Drugs: a Case-Control Study. 2013 , 5, 53-64	
76	Psoriasis and Comorbidities. 2014 , 277-299	
75	Adalimumab. 2014 , 159-175	
74	Risk factors for comorbidities in Czech psoriatic patients: results of a hospital-based case-control study. 2014 , 158, 288-94	2

- 73 Desynchronizing effects of comorbid pathology: psoriasis and arterial hypertension. **2014**, 20, 21-24
- 72 Analysis of Risk Factors for Psoriasis Recurrence Using Proportional Rates Model. **2014**, 1, 2
- 71 Psoriasis and Aging. **2015**, 1-7
- 70 HOSPITAL BASED STUDY ON DYSLIPIDEMIA AND PSORIASIS. **2015**, 4, 15224-15227
- 69 PROFILE OF PSORIASIS AMONG IN PATIENTS OF DERMATOLOGY DEPARTMENT OF A GOVERNMENT TERTIARY CARE TEACHING HOSPITAL IN MYSORE: A MEDICAL RECORD BASED STUDY. **2016**, 5, 959-963
- 68 Psoriasis and Aging. **2017**, 1065-1070
- 67 Severely Obese 42-Year-Old with Psoriasis. **2017**, 63-71
- 66 Evidence of a common causal relationship between body mass index and inflammatory skin disease: a Mendelian Randomization study. 2
- 65 High-sensitivity C-reactive protein/adiponectin ratio and risk factors of atherosclerosis in patients with lichen planus. **2018**, 15, 62-67
- 64 Association between Homocysteine Levels and Psoriasis: A Meta-Analysis. **2019**, 31, 378-386 2
- 63 Cardiovascular Risk in Psoriasis Patients: Clinical, Functional and Morphological Parameters. **2019**, 113, 242-249 1
- 62 SIK GRÖEN DERMATOLOJİK HASTALIKLARIN EKONOMİK YÖNÜ, 35-51
- 61 The relationship between alexithymia, anxiety, depression, and severity of the disease in psoriasis patients. 1
- 60 Correlation between Seborrheic Dermatitis and Metabolic Syndrome in Patients Referred to Sina Hospital of Hamadan. **2020**, 27, 13-20 1
- 59 A CLINICO-EPIDEMIOLOGICAL STUDY OF PSORIASIS IN A TERTIARY CARE HOSPITAL IN PATNA, BIHAR. **2020**, 53-54
- 58 Association between Vaspin rs2236242 Gene Polymorphism and Psoriasis Vulgaris. **2020**, 33, 317-322 1
- 57 Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. **2020**, 19, 214 2
- 56 The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients. **2021**, 8, 203-211

55	Psoriasis and Its Association with Various Biochemical Parameters - A Clinico-Epidemiological Study. 2020 , 9, 900-904	
54	Efficacy of interleukin 17 inhibitor therapy in overweight and obese psoriasis patients (preliminary data). 2021 , 31-36	
53	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis. 2021 , 12, 774808	2
52	Psoriasis and psoriatic arthritis: a clinical review. 2008 , 23-39	
51	Psoriasis. 2008 , 207-216	
50	Obesity. 2009 , 143-153	
49	Adalimumab for Psoriasis. 2021 , 153-172	
48	Psoriasis and Comorbidities. 2021 , 363-397	
47	Psoriasis: Epidemiology, Potential Triggers, Disease Course. 2021 , 27-37	
46	Traditional Systemic Therapy I: Methotrexate and Cyclosporine. 2021 , 103-118	
45	Ustekinumab in the therapy of chronic plaque psoriasis. 2009 , 3, 159-68	18
44	Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. 2009 , 9, 1-66	3
43	Malaysian Clinical Practice Guideline for the Management of Psoriasis Vulgaris: Summary of recommendations for management in primary healthcare setting. 2014 , 9, 16-21	3
42	Biologic safety in psoriasis: review of long-term safety data. 2015 , 8, 30-42	10
41	A specific molecular signature for psoriasis and eczema. 2015 , 3, 76	1
40	Characterization of the abnormal lipid profile in Chinese patients with psoriasis. 2015 , 8, 15280-4	5
39	More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis. 2016 , 41, 388-90	2
38	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. 2016 , 9, S5-S29	2

37	Psoriasis and Psoriatic Arthritis. 2017 , 10, S16-S25		3
36	Multifaceted Analysis of IL-23A- and/or EB13-Including Cytokines Produced by Psoriatic Keratinocytes. 2021 , 22,		0
35	DIFFERENCES IN CLINICAL FEATURES AND COMORBID BURDEN BETWEEN HLA-C*06:02 CARRIER GROUPS IN MORE THAN 9,000 PEOPLE WITH PSORIASIS. <i>Journal of Investigative Dermatology</i> , 2021	4.3	0
34	Beyond the Skin Plaques: Psoriasis and Its Cardiovascular Comorbidities.. 2021 , 13, e19679		1
33	Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease.. 2022 ,		3
32	Risco cardiovascular na artrite psoriásica. 2015 , 28-34		
31	Pathogenesis. 2022 , 13-22		
30	Angiotensin-Converting Enzyme Activity May Predict Disease Severity in Psoriasis. 2022 , 2, 15-23		0
29	Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	2
28	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. <i>Programme Grants for Applied Research</i> , 2022 , 10, 1-240	1.5	
27	The association between platelet indices and presence and severity of psoriasis: a systematic review and meta-analysis.. <i>Clinical and Experimental Medicine</i> , 2022 , 1	4.9	0
26	Do patients with psoriasis are at higher risk for atherogeneity? A case-control study.. <i>Journal of Cosmetic Dermatology</i> , 2022 ,	2.5	
25	Lipid Profiles and Cardiovascular Risk in Patients with Oral Lichen Planus.. <i>Dentistry Journal</i> , 2022 , 10,	3.1	0
24	Psöatik Artrit Alt Tiplerinde Metabolik Sendrom Sileve Kardiyovaskler Risk Faktölerinin Deörlendirilmesi. <i>Uludaüiversitesi Tö Fakötesi Dergisi</i> ,		
23	Curcumin: A review of its efficacy in the management of psoriasis. <i>Drug Delivery Letters</i> , 2022 , 12,	0.8	0
22	Rational external therapy of scalp psoriasis. <i>Vestnik Dermatologii I Venerologii</i> , 2013 , 89, 91-94	0.4	
21	Pathogenic aspects of treatment of psoriatic patients. <i>Vestnik Dermatologii I Venerologii</i> , 2014 , 90, 86-90.	0.4	4
20	Interleukin 12/23 inhibitors. 2013 , 319-332.e2		

- 19 Is It Prime Time for Statin Therapy in Psoriasis?. *Journal of Investigative Dermatology*, **2022**, 142, 1519-1523
- 18 Comorbidity in Adult Psoriasis: Considerations for the Clinician. *Psoriasis: Targets and Therapy*, Volume 12, 139-150 2.4 0
- 17 Psoriasis hastalarında sigara içme durumu ile yaşam kalitesi arasındaki ilişki ve hastaların tedaviye yanıtı. *Cukurova Medical Journal*, **2022**, 47, 792-799 0.1
- 16 The link between total antioxidant status, total oxidant status, arylesterase activity, and subgingival microbiota in psoriasis patients.
- 15 Dysbiosis in imiquimod-induced psoriasis alters gut immunity and exacerbates colitis development. **2022**, 40, 111191 2
- 14 Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways. **2022**, 23, 9063 0
- 13 Psoriasis: is it a risk factor for cardiovascular diseases?. 1-6
- 12 Mitochondrial dysfunction: The pathological link between psoriasis and insulin resistance? 0
- 11 Tailored biological treatment for patients with moderate to severe psoriasis. 0
- 10 Psoriasis: Beyond the Skin. 90-95 0
- 9 Evaluation of some immunological parameters in psoriasis patients. **2022**, 0
- 8 Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients. **2022**, 12, 1870 1
- 7 Liver fibrosis for the dermatologist: a review. 0
- 6 Is hypertension an extra-intestinal manifestation of inflammatory bowel disease?. **2023**, 11, 7-8 0
- 5 Effects of Metabolic Syndrome on Cardiovascular Outcomes of Psoriatic Patients with Coronary Artery Disease: A Single Center Retrospective Cohort Study. Volume 16, 1003-1012 0
- 4 Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. **2023**, 12, 1162 0
- 3 Psoriasis y riesgo cardiovascular. **2023**, 0
- 2 Handlungsempfehlungen zur individuellen Risikoermittlung von Komorbiditäten bei erwachsenen Patienten mit Psoriasis. 0

- 1 Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians. 103, adv5087

○